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Antiplatelet treatment compared with anticoagulation 
treatment for cervical artery dissection (CADISS): 
a randomised trial
The CADISS trial investigators*
Summary
Background Extracranial carotid and vertebral artery dissection is an important cause of stroke, especially in young 
people. In some observational studies it has been associated with a high risk of recurrent stroke. Both antiplatelet 
drugs and anticoagulant drugs are used to reduce risk of stroke but whether one treatment strategy is more eﬀ ective 
than the other is unknown. We compared their eﬃ  cacy in the Cervical Artery Dissection in Stroke Study (CADISS), 
with the additional aim of establishing the true risk of recurrent stroke. 
Methods We did this randomised trial at hospitals with specialised stroke or neurology services (39 in the UK and 
seven in Australia). We included patients with extracranial carotid and vertebral dissection with onset of symptoms 
within the past 7 days. Patients were randomly assigned (1:1) by an automated telephone randomisation service to 
receive antiplatelet drugs or anticoagulant drugs (speciﬁ c treatment decided by the local clinician) for 3 months. 
Patients and clinicians were not masked to allocation, but investigators assessing endpoints were. The primary 
endpoint was ipsilateral stroke or death in the intention-to-treat population. The trial was registered with EUDract 
(2006-002827-18) and ISRN (CTN44555237).
Findings We enrolled 250 participants (118 carotid, 132 vertebral). Mean time to randomisation was 3·65 days 
(SD 1·91). The major presenting symptoms were stroke or transient ischaemic attack (n=224) and local symptoms 
(headache, neck pain, or Horner’s syndrome; n=26). 126 participants were assigned to antiplatelet treatment versus 
124 to anticoagulant treatment. Overall, four (2%) of 250 patients had stroke recurrence (all ipsilateral). Stroke or 
death occurred in three (2%) of 126 patients versus one (1%) of 124 (odds ratio [OR] 0·335, 95% CI 0·006–4·233; 
p=0·63). There were no deaths, but one major bleeding (subarachnoid haemorrhage) in the anticoagulant group. 
Central review of imaging failed to conﬁ rm dissection in 52 patients. Preplanned per-protocol analysis excluding 
these patients showed stroke or death in three (3%) of 101 patients in the antiplatelet group versus one (1%) of 
96 patients in the anticoagulant group (OR 0·346, 95% CI 0·006–4·390; p=0·66).
Interpretation We found no diﬀ erence in eﬃ  cacy of antiplatelet and anticoagulant drugs at preventing stroke and 
death in patients with symptomatic carotid and vertebral artery dissection but stroke was rare in both groups, and 
much rarer than reported in some observational studies. Diagnosis of dissection was not conﬁ rmed after review in 
many cases, suggesting that radiographic criteria are not always correctly applied in routine clinical practice.
Funding Stroke Association.
Copyright ©Markus et al. Open Access article distributed under the terms of CC BY.
Introduction
Cervical artery dissection accounts for only 1–2% of all 
ischaemic strokes, but in young and middle-aged 
people it accounts for 10–25% of strokes.1 Some studies 
suggest a signiﬁ cantly increased risk of stroke in 
patients presenting with dissection either with local 
symptoms, such as headache and Horner’s syndrome, 
or with stroke or transient ischaemic attack, with 
estimates of the risk of secondary stroke after 
presentation of 15–20%,2–4 although other studies have 
reported a much lower proportion.5 These studies 
suggested that most strokes occurred soon after initial 
onset of symptoms. Embolism from thrombus forming 
at the dissection site is thought to play the major part in 
stroke pathogenesis.6 This suggestion is supported by 
transcranial Doppler studies7,8 showing cerebral micro-
emboli soon after dissection, and by the distribution of 
infarcts after dissection, which suggests an embolic 
pattern.9
The risk of early recurrence of stroke has led many 
clinicians to advocate the use of anticoagulation from 
presentation until 3 or 6 months after dissection. 
However others believe that antiplatelet drugs might be 
suﬃ  cient.10 Anticoagulants might prevent embolism 
from a fresh thrombus but they are also more hazardous 
than antiplatelet drugs and can result in extension of the 
intramural haemorrhage, which occurs in a third of 
patients according to MRI.11 No data exist from 
randomised controlled trials assessing the relative 
eﬃ  cacy of the two treatments.
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The Cervical Artery Dissection In Stroke Study (CADISS) 
was established to compare the eﬀ ectiveness of antiplatelet 
drugs with anticoagulant drugs for the prevention of 
recurrent stroke in patients with carotid and vertebral 
dissection. It was established as a phase 2 feasibility trial 
with a planned sample size of 250 to enable accurate 
estimation of the rate of recurrent stroke and thereby 
samples sizes for a deﬁ nitive phase 3 trial to be calculated.
Methods
Study design and participants
We did this randomised open-label parallel randomised 
trial at hospitals with specialised stroke or neurology 
services in the UK (n=39) and Australia (n=7). The full 
study protocol has been previously published.12
We enrolled patients from inpatient or outpatient 
services who had extracranial carotid or vertebral artery 
dissection with onset of symptom within the past 7 days, 
and imaging evidence of deﬁ nite or probable dissection. 
Patients who had had stroke or transient ischaemic attack 
within the past 7 days were eligible. Imaging evidence of 
dissection had to be by MRI or magnetic resonance 
angio graphy, CT angiography, or intra-arterial angio-
graphy: although patients could be randomised on the 
basis of ultrasound alone, subsequent conﬁ rmation with 
MRI, magnetic resonance angiography, or CT angio-
graphy was required.
Exclusion criteria were: intracranial cerebral artery 
dissection; contraindications to either antiplatelet or 
anticoagulation drugs, including active peptic ulceration 
or bleeding peptic ulcer within 1 year; use of antiplatelet 
or anticoagulants drugs for other reasons (eg, prosthetic 
heart valves) for which the treatment cannot be replaced 
with either antiplatelet or anticoagulant drugs; and 
pregnancy.
The study was approved by ethics committees of all 
participating centres in Australia and the UK. All patients 
gave written informed consent  before enrolment.
Randomisation and masking
Patients were randomly assigned (1:1) to either 
antiplatelet treatment or anticoagulation treatment by an 
automated telephone randomisation service provided by 
the University of Aberdeen (Aberdeen, UK). Both 
patients and clinicians were aware of treatment allo-
cation, but an adjudication committee that assessed all 
primary and secondary endpoints were masked to 
treatment allocation.
Procedures
The choice of antiplatelet drug or anticoagulant drug was 
at the discretion of the local physician. Antiplatelet 
treatments included aspirin, dipyridamole, or clopidogrel 
alone or in combination. For patients assigned to 
anticoagulation, treatment with heparin (either un frac-
tionated heparin or a therapeutic dose of low-molecular-
weight heparin) was followed by warfarin, aiming for an 
international normalised ratio of 2–3. Novel oral 
anticoagulants were not used. Low-dose heparin pro-
phylaxis for prevention of deep-vein thrombosis was not a 
contraindication, but its use was recorded. Such 
prophylaxis could be continued after randomisation in the 
antiplatelet group at the discretion of the local clinician.
Patients were followed up at 3 months after randomi-
sation, when data for outcome and occurrence of 
recurrent stroke and transient ischaemic attack were 
recorded. Repeat imaging with magnetic resonance 
angiography or CT angiography to assess vessel recana-
lisation was done whenever possible at the 3-month 
follow up visit.
Outcomes
The primary endpoint was ipsilateral stroke or death (any 
cause) within 3 months of randomisation in the 
intention-to-treat population. For vertebral dissection, an 
ipsilateral event was deﬁ ned as a recurrent event in the 
vertebrobasilar territory. Secondary endpoints were: 
ipsilateral transient ischaemic attack (including 
amaurosis fugax), stroke, or death (any cause); any stroke 
or death (any cause); any stroke, death, or major bleeding; 
any stroke; any transient ischaemic attack (including 
amaurosis fugax) or stroke; death; residual stenosis 
(>50%); and major bleeding.
Major bleeding was deﬁ ned according to the Inter-
national Society on Thrombosis and Haemostasis 
deﬁ nition:13 fatal bleeding or symptomatic bleeding in a 
critical area or organ, such as intracranial, intraspinal, 
intraocular, retroperitoneal, intra-articular, or pericardial, 
250 patients enrolled
126 assigned to 
antiplatelets
124 assigned to 
anticoagulants
126 received 
antiplatelets
124 received 
anticoagulants
126 included in 
intention-to-
treat analysis
124 included in 
intention-to-
treat analysis
25 did not meet 
inclusion criteria
24 did not meet
imaging  
criteria
1 delayed 
randomisation
28 did not meet 
inclusion criteria
28 did not meet
imaging 
criteria
101 included in 
per-protocol 
analysis
96 included in 
per-protocol 
analysis
Figure: Trial proﬁ le
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or intramuscular with compartment syndrome, or bleed-
ing causing a fall in haemoglobin concentration of 
1·24 units or more, or leading to transfusion of two or 
more units of whole blood or red cells. Stroke was 
deﬁ ned by the WHO deﬁ nition14 as rapidly developing 
clinical signs of focal (or global) disturbance of cerebral 
function, lasting more than 24 h or leading to death, with 
no apparent cause other than that of vascular origin.
Statistical analysis
We planned to enrol 250 participants on the basis of 
observational studies.2–4 We did no interim analyses.
All enrolled patients were included in the intention-to-
treat population. We also did a per-protocol analysis, 
which excluded any patient who did not meet inclusion 
criteria for any reason, including failure to conﬁ rm 
diagnosis of dissection on central review of imaging. We 
calculated exact CIs with the binomial (Clopper-Pearson) 
exact method. We compared the treatment eﬀ ect in each 
group by exact logistic regression (Stata, version 13). We 
did the other analyses with SPSS (version 20).
We did power calculations to estimate the sample size 
needed for a deﬁ nitive phase 3 trial with an online power 
calculator. These calculations were based on the 
combined endpoint of stroke, death, and major bleeding, 
with a power of 0·8 and a p value of 0·05.
This trial is registered with EudraCT (2006-002827-18) 
and ISRN (CTN44555237) and was adopted by the 
English National Institute for Health Research Clinical 
Research Network (2181).
Role of the funding source
The funder had no role in study design, data collection, 
analysis, or interpretation, writing of the report, or the 
decision to submit for publication. All authors had full 
access to all the data in the study. The ﬁ nal decision to 
submit the report for publication was made by HSM.
Results
We recruited 250 patients between Feb 24, 2006, and 
June 17, 2013. 118 had carotid dissection and 132 had 
vertebral arterial dissection. Mean time to randomisation 
was 3·65 days (SD 1·91). 174 (70%) of participants were 
male. Mean age was 49 years (SD 12, range 18–87). 
126 participants were randomly assigned to antiplatelet 
treatment and 124 to anticoagulation treatment (ﬁ gure). 
The major presenting symptoms were cerebral ischaemic 
in 224 patients (195 ischaemic stroke, 29 transient 
ischaemic attack) and local symptoms in 26 patients 
(22 headache, 22 neck pain, four Horner’s syndrome). 
Table 1 shows baseline characteristics. All patients were 
followed up for 3 months.
In the antiplatelet group, 28 (22%) of 126 patients 
received aspirin alone, 42 (33%) received clopidogrel 
alone, one (1%) received dipyridamole alone, 35 (28%) 
received aspirin and clopidogrel, and 20 (16%) received 
aspirin and dipyridamole. In the anticoagulant group, 
112 (90%) of 124 patients received heparin and warfarin 
and 12 (10%) received warfarin alone. 
Original brain imaging and angiographic imaging 
was reviewed for all patients throughout the study and 
before the database was locked. Dissection was 
conﬁ rmed for 198 patients (102 in the antiplatelet group, 
96 in the anticoagulant group). For one patient in the 
antiplatelet group, although recruited within 7 days, 
randomisation was not done until day 9 because of a 
technical error. Therefore the per-protocol analysis 
included 197 patients (101 in the antiplatelet group, 96 in 
the anticoagulant group). 
For the online power calculator 
see https://www.sealedenvelope.
com/power/binary-superiority/
Intention-to-treat population Per-protocol population
Antiplatelet 
group (n=126)
Anticoagulant 
group (n=124)
Antiplatelet 
group (n=101)
Anticoagulant 
group (n=96)
Age (years) 49·3 (12) 49·2 (12) 48·5 (12) 48·1 (11)
Men 87 (69%) 87 (70%) 69 (68%) 66 (69%)
Site of dissection
Internal carotid artery 58 (46%) 60 (48%) 51 (50%) 47 (49%)
Vertebral artery 68 (54%) 64 (52%) 50 (50%) 49 (51%)
Presenting signs and symptoms
Amaurosis fugax 4 (3%) 5 (4%) 4 (4%) 4 (4%)
Retinal infarction 0 (0%) 1 (1%) 0 (0%) 1 (1%)
Transient ischaemic attack 27 (21%) 20 (16%) 20 (20%) 15 (16%)
Ischaemic stroke 93 (74%) 101 (81%) 74 (73%) 77 (80%)
Headache 84 (67%) 83 (67%) 68 (67%) 68 (71%)
Neck pain 57 (45%) 63 (51%) 41 (41%) 51 (53%)
Horner’s syndrome 26 (21%) 34 (27%) 24 (24%) 29 (30%)
Time between symptoms and 
randomisation (days)
3·9 (1·8) 3·4 (2·0) 3·8 (1·8) 3·3 (2·1)
Modiﬁ ed Rankin score 2·1 (1·5) 2·1 (1·5) 2·1 (1·6) 2·2 (1·5)
Received stroke thrombolysis 12 (10%) 10 (8%) 10 (10%) 8 (8%)
Risk factors
Treated hypertension 29 (23%) 26 (21%) 21 (21%) 19 (20%)
Diabetes 5 (4%) 5 (4%) 3 (3%) 3 (3%)
Treated hyperlipidaemia 16 (13%) 19 (15%) 12 (12%) 11 (12%)
Ever smoked 63 (50%) 66 (53%) 52 (52%) 51 (53%)
Migraine 20 (16%) 25 (20%) 15 (15%) 22 (23%)
History of trauma to head or neck 
within past 28 days
32 (25%) 21 (17%) 26 (26%) 16 (17%)
Systolic blood pressure (mm Hg) 137·7 (20·9) 135·9 (19·9) 137·78 (20·3) 135·1 (19·5)
Diastolic blood pressure (mm Hg) 81·9 (12·2) 84·0 (15·1) 82·2 (12·1) 84·2 (15·0)
Cholesterol concentration (mmol/L)* 5·22 (1·14) 5·16 (1·32) 5·21 (1·19) 5·18 (1·38)
Diagnostic imaging
CT 110 (87%) 105 (85%) 87 (87%) 82 (85%)
MRI 103 (82%) 93 (75%) 80 (79%) 70 (73%)
Angiography
Any 122 (97%) 120 (97%) 99 (98%) 95 (99%)
Magnetic resonance angiography 94 (75%) 83 (67%) 73 (72%) 66 (69%)
CT angiography 54 (43%) 58 (47%) 47 (47%) 46 (48%)
Digital subtraction angiography 1 (1%) 3 (2%) 1 (1%) 3 (3%)
Data are mean (SD) or n (%). *Measured for 101 participants in the antiplatelet group and 108 participants in the 
anticoagulant group.
Table 1: Baseline characteristics
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Overall, stroke recurred in four (2%) of 250 patients in 
the intention-to-treat population: three in the antiplatelet 
group versus one in the anticoagulant group, all 
ipsilateral (appendix p 2). All recurrent strokes occurred 
in patients in whom the presenting symptom was stroke 
(four [2%] of 194 patients; three carotid, one 
vertebrobasilar).No deaths occurred, therefore the 
primary endpoint of ipsilateral stroke or death occurred 
in three (2%) of 126 patients in the antiplatelet group 
versus one (1%) of 124 in the anticoagulant group (odds 
ratio 0·335, 95% CI 0·006–4·233; p=0·63; table 2). In 
the per-protocol population, stroke recurred in four (2%) 
of 196 patients overall, and in four (3%) of 151 who 
presented with stroke (appendix).
For the intention-to-treat population, ipsilateral 
transient ischaemic attack occurred in one (1%) of 
126 patients in the antiplatelet group versus four (3%) of 
124 patients in the anticoagulant group (one [1%] of 101 vs 
three [3%] of 96 in the per-protocol population). Other 
transient ischaemic attack occurred in only one patient 
in the antiplatelet group, in both the intention-to-treat 
and per-protocol populations (appendix).
None of the secondary endpoints diﬀ ered signiﬁ cantly 
between treatment groups. Results in the intention-to-
treat and per-protocol populations were much the same 
(table 2).
Table 3 shows adverse events. One major bleed 
occurred in the anticoagulant group (none in the anti-
platelet group), in a patient with vertebral dissection with 
extension intracranially who developed a subarachnoid 
haemorrhage. This patient presented with headache with 
no focal neurological symptoms and CT brain imaging 
showed intraventricular blood. Two minor bleeds 
occurred in the anticoagulant group (one haematuria 
and one haemoptysis), and none in the antiplatelet 
group.
To establish whether recurrent events might have 
occurred before recruitment and randomisation, we did 
a post-hoc analysis of patients presenting with stroke in 
whom previous transient ischaemic attack or minor 
stroke had occurred. In the intention-to-treat population, 
nine such patients were present in the anticoagulant 
group versus ten in the antiplatelet group (seven vs seven 
in the per-protocol population). The mean time between 
previous symptoms and subsequent stroke was 3·4 days 
(SD 5·5, range 0·04–21; median 1 day, IQR 0·25–4·0) in 
the intention-to-treat population, and 3·9 days (SD 6·3, 
range 0·13–21; median 1 day, IQR 0·3–5·0) in the per-
protocol population.
Intention-to-treat population Per-protocol population
Antiplatelet 
group (n=126)
Anticoagulant 
group (n=124)
OR (95% CI)* p value Antiplatelet 
group (n=101)
Anticoagulant 
group (n=96)
OR (95% CI)* p value
Ipsilateral stroke or death 3 (2%) 1 (1%) 0·335 (0·006–4·233) 0·63 3 (3%) 1 (1%) 0·346 (0·006–4·390) 0·66
Secondary endpoints
Any stroke or death 3 (2%) 1 (1%) 0·335 (0·006–4·233) 0·63 3 (3%) 1 (1%) 0·346 (0·006–4·390) 0·66
Any stroke, death, or major bleed 3 (3%) 2 (2%) 0·673 (0·055– 5·983) 1·00 3 (3%) 2 (2%) 0·696 (0·057–6·220) 1·00
Any stroke 3 (2%) 1 (1%) 0·335 (0·006–4·233) 0·63 3 (3%) 1 (1%) 0·346 (0·006–4·390) 0·66
Ipsilateral stroke, TIA, or death 4 (3%) 5 (4%) 1·280 (0·268–6·614) 0·98 4 (4%) 4 (4%) 1·054 (0·190–5·835) 1·00
Any stroke or TIA 5 (4%) 5 (4%) 1·017 (0·228–4·540) 1·00 5 (5%) 4 (4%) 0·836 (0·161–4·015) 1·00
Major bleeding 0 (0%) 1 (1%) ·· ·· 0 (0%) 1 (1%) ·· ··
Death 0 (0%) 0 (0%) ·· ·· 0 (0%) 0 (0%) ·· ··
Data for presence of residual stenosis (>50%) at 3 months have not yet been analysed. OR=odds ratio. TIA=transient ischaemic attack. *Tested with exact logistic regression. 
 Table 2: Outcomes within 3 months
Antiplatelet 
group (n=126)
Anticoagulant 
group (n=124)
Abdominal pain 0 (0%) 1 (1%)
Abnormal liver function test 0 (0%) 1 (1%)
Allergic reaction 1 (1%) 0 (0%)
Chest pain 0 (0%) 1 (1%)
Diplopia 1 (1%) 0 (0%)
Dizziness 0 (0%) 1 (1%)
Haematuria 0 (0%) 1 (1%)
Haemoptysis 0 (0%) 1 (1%)
Headache 4 (3%) 3 (2%)
Hip pain 0 (0%) 1 (1%)
Hydrocephalus 0 (0%) 1 (1%)
Myocardial infarction 1 (1%) 0 (0%)
Nausea or vomiting 3 (2%) 1 (1%)
Neck pain 0 (0%) 1 (1%)
Numbness 0 (0%) 1 (1%)
Ophthalmic nerve neuralgia 1 (1%) 0 (0%)
Pneumonia 1 (1%) 1 (1%)
Seizure 0 (0%) 2 (2%)
Subarachnoid haemorrhage 0 (0%) 1 (1%)
Vision loss 0 (0%) 1 (1%)
Worsening of ataxia 1 (1%) 0 (0%)
Worsening of Horner’s syndrome 0 (0%) 1 (1%)
Four patients (two in each treatment group) had two adverse events; no patient 
had more than two adverse events.
 Table 3: Adverse events
See Online for appendix
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To assess the feasibility of a phase 3 trial, we did power 
calculations with the per-protocol data, and the composite 
outcome of stroke, death, or major bleeding (2·08%, 
95% CI 0·25–7·32 in the anticoagulant group and 
2·97%, 0·62–8·44 in the antiplatelet group). We 
calculated that a study with a power of 0·8 and 
signiﬁ cance level of 0·05 would require a sample size of 
4876 in each group.
Discussion
The results of our study, to our knowledge the ﬁ rst 
randomised trial of antiplatelet treatment compared with 
anticoagulant treatment for extracranial carotid and 
vertebral artery dissection (panel), show that recurrent 
stroke at 3 months is rare, with no signiﬁ cant diﬀ erence 
between the two treatments. Although more strokes 
occurred in the antiplatelet group than in the 
anticoagulant group, this diﬀ erence was counterbalanced 
by one major subarachnoid haemorrhage in the 
anticoagulant group.
The risk of recurrent events was lower than that reported 
in some observational studies. One of the ﬁ rst studies,2 
which included 80 patients with carotid dissection (29 
retrospectively and 51 prospectively recruited) reported 
recurrences in 17 (41%) of 41 patients presenting with 
transient ischaemic attack. In a prospective multicentre 
Canadian study,3 in which follow-up data were available 
for 105 individuals, nine patients had stroke after 
presentation with either carotid or vertebral dissection, 
although ﬁ ve recurrences were before study enrolment; 
the time between enrolment and onset of symptoms was 
not documented. By contrast, a retrospective analysis15 of 
data from 298 patients with carotid dissection, all treated 
with either antiplatelet or anticoagulant drugs, reported 
fewer recurrences: 0·3% had ischaemic stroke, 3·4% had 
transient ischaemic attack, and 1·0% had retinal 
ischaemia. New ischaemic events were signiﬁ cantly more 
common in patients with ischaemic events at onset 
(6·2%) than in patients with local symptoms or 
asymptomatic patients (1·1%). The results from the non-
randomised part of CADISS6 reported a similarly low 
proportion: two (2%) recurrent strokes occurred during 
3-month follow-up of 87 individuals with both carotid and 
vertebral artery dissection; however, mean time from 
symptom onset was 10·8 days (SD 7·0, range 1–31). In a 
trial setting, patients might have been recruited after they 
had already had their recurrent stroke; however, few 
patients in our study had such symptoms, suggesting this 
eﬀ ect was not the reason for the diﬀ erence in recurrence 
of stroke in CADISS compared with previous observational 
studies.
Because recurrences were rare, any deﬁ nitive study 
examining this question is likely to need a very large 
sample size. Power calculations based on the per-protocol 
data and using the endpoint of stroke, death, or major 
bleeding gave a required total sample size of almost 
10 000 participants, which will be diﬃ  cult to recruit. 
However, because the outcomes were rare, the 95% CIs 
for the endpoints were large and therefore the number of 
participants needed according to our calculation should 
be considered a rough estimate.
Diagnosis of dissection could not be centrally conﬁ rmed 
on imaging review in about a ﬁ fth of participants, despite 
evidence of dissection on angio graphic imaging or cross-
sectional imaging through the vessel wall. The failure to 
conﬁ rm diagnosis was mainly caused by two factors. 
First, imaging was of poor quality for some participants 
and it was impossible to be sure of the diagnosis. Second, 
central review of imaging suggested an alternative 
diagnosis in some patients for whom imaging was of 
adequate quality. The most common alternative diagnoses 
were atherosclerosis, an atretic rather than dissected 
vertebral artery, a narrowed artery without any deﬁ nite 
evidence of dissection and, in one case, adherent 
thrombus without clear evidence of dissection.
Several radiographic features suggest dissection, 
including appearance of a ﬂ ap, tapering stenosis or 
pseudoaneurysm on angiography, and imaging of the 
arterial wall showing intramural blood. The diﬃ  culties 
associated with diagnosis of dissection have been well-
documented.16 For imaging of the vessel, diﬃ  culties 
include limited spatial resolution, the tortuous course of 
arteries, variability in normal vessel calibre, presence of a 
thick bone covering, and adjacent veins. Imaging the 
vertebral arteries is more diﬃ  cult than imaging the 
carotid arteries because of their smaller size, the fact that 
one is often atretic, and because ﬂ ow-related 
enhancement of the vertebral plexus surrounding the 
artery can mimic intramural blood.16 This greater 
diﬃ  culty in diagnosis of vertebral dissection was shown 
by the lower proportion of conﬁ rmed diagnoses for 
vertebral artery dissection (100 of 132) versus carotid 
dissection (98 of 118). However, the low proportion of 
conﬁ rmed diagnoses and variations between recruitment 
sites suggest that training and quality control need to be 
improved. We did not use prespeciﬁ ed imaging criteria; 
doing so might have improved the accuracy of diagnosis.
CADISS was designed as a pragmatic trial and therefore 
the choice of antiplatelet drugs was at the discretion of 
the clinician. Prescription of dual antiplatelet treatment 
for all patients might have improved eﬃ  cacy. Another 
limitation is that many patients did not have imaging 
conﬁ rmation after central review; however, this 
shortcoming provides important information about 
routine clinical practice in the real world and a strength of 
the study was central review of imaging for all patients. 
Disease heterogeneity—eg, carotid versus vertebral 
dissection, or recent stroke versus local symptoms only—
might have caused diﬀ erent groups to respond diﬀ erently 
to treatments. Endpoints were too rare to assess such 
subgroups, but all recurrent strokes occurred in patients 
who had presented with stroke, consistent with previous 
data from obser vational studies,15 suggesting this group 
are at the highest risk of recurrent event.
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Generalisability is important in any clinical trial. To 
estimate the proportion of patients presenting with 
dissection who were recruited to the study, during the 
early part of CADISS, patients who were not randomly 
assigned (either because they did not meet the inclusion 
criteria or because the clinician or patient did agree to 
randomisation) could be entered into a non-randomised 
arm.6 During this period, while 77 participants were 
recruited to the randomised arm, 88 patients screened for 
inclusion were not randomly assigned and instead 
entered the observational arm. Reasons for exclusion 
from the randomised arm were: presentation after 7 days 
(n=53), contraindication to antiplatelet or anticoagulant 
drugs (n=12), already taking antiplatelet or anticoagulation 
drugs for other reasons (n=5), patient or physician 
unwilling to randomise (n=18).6 These ﬁ ndings show that 
some patients (35 [21%] of 165) presenting within the 
7-day window for inclusion in the randomised study were 
excluded. 
In the observational arm of CADISS, stroke occurred in 
one (2%) of 59 patients treated with antiplatelet drugs, 
and in one (4%) of 28 patients treated with anticoagulant 
drugs. Some patients presenting with dissection, and 
perhaps particularly with very early, severe, recurrent 
stroke, might not have been included in either the 
observational or the randomised part of the study because 
they could not provide consent. Inclusion of patients 
within 24 h of onset of symptoms might have helped us to 
capture early recurrent strokes. However, some patients 
with dissection, particularly those with local symptoms, 
did not present on the day of onset. Furthermore, in 
the UK, a diagnosis of dissection might not be made until 
a couple of days after presentation because diagnostic 
angiographic or cross-sectional MRI is not always done at 
presentation. We therefore decided that a 7-day window 
would provide generalisable results, and also ensure that 
recruitment was feasible.
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Sheﬃ  eld, UK), John Norris (St George’s University of London, London, 
UK); trial managers—Jennifer Peycke, Melina Willson, Cara Hicks, 
Elizabeth Hayter; study neuroradiologists— Jeremy Madigan, 
Andrew Clifton; coordinating centre clinical fellows and telephone 
follow-up—Ranjith Menon, Fiona Kennedy, Usman Khan; statistical 
analysis—Adina Feldman, Matt Hollocks, Hugh S Markus; imaging 
review—Alice King, Jeremy Madigan; steering committee—
Hugh S Markus, John Norris, Graham S Venables, Sally Kerry, 
Ahamed Hassan, Chris Levi; data monitoring committee—Gary A Ford 
(Chair), Philip M W Bath, Chris Weir; adjudication committee—
Lalit Kalra (chair), Denis Briley, Ajay Bhalla.
Participating centres (number of patients enrolled; principal investigator)
UK: Aberdeen Royal Inﬁ rmary, Aberdeen (12; John Reid), Aintree 
University Hospital, Liverpool (13; Raj Kumar), Airedale General 
Hospital, Keighley (3; Samantha Mawer, Matthew Smith), Brighton and 
Sussex University Hospital, Brighton (3; Khalid Ali), Charing Cross 
Hospital, London (5; Pankaj Sharma), Cheltenham General and 
Gloucester Royal Hospitals, Cheltenham and Gloucester (1; 
Dipankar Dutta), Derriford Hospital, Plymouth (1; Azlisham Mohd Nor), 
Frenchay Hospital, Bristol (1; Rose Boswell, Neil Baldwin), Guy’s and 
St Thomas’, London (6; Anthony Rudd), Heartlands Hospital, 
Birmingham (0; David Stanley), Hope Hospital, Kent and Canterbury 
Hospital, Canterbury (3; Isle Burger), King’s College Hospital, London 
(9; Lalit Kalra), Leeds General Hospital, Leeds (6; Ahamed Hassan), 
Musgrove Park Hospital, Taunton (1; Christopher Price), Newcastle 
Hospitals NHS Foundation Trust, Newcastle-upon-Tyne (5; Anand Dixit), 
Ninewells Hospital, Dundee (6; Ronald MacWalter), Northwick Park, 
Harrow (1; David Cohen), Pinderﬁ elds General Hospital, Wakeﬁ eld 
(2; Richard Davey), Queen Elizabeth Hospital, Gateshead (1; 
Tim Cassidy), Queen Elizabeth Queen Mother Hospital, Margate 
(6; Gunarathnam Gunathilagan), Royal Bournemouth Hospital, 
Bournemouth (2; Damian Jenkinson), Royal Cornwall Hospitals NHS 
Trust, Truro (5; Frances Harrington), Royal Devon and Exeter Hospital, 
Exeter (7; Martin James), Royal Hallamshire Hospital, Sheﬃ  eld 
(15; Graham Venables), Royal Hampshire Hospital, Winchester 
(1; Nigel Smyth), Royal Preston Hospital, Preston (1; Hedley Emsley), 
Royal United Hospital, Bath (4; Louise Shaw), Southampton General 
Hospital, Southampton (2; Joanna Lovett), Southend Hospital, Southend 
(11; Paul Guyler), Southern General Hospital, Glasgow (3; Keith Muir), 
St George’s Hospital, London (58; Hugh S Markus), Royal London 
Hospital, London (1; Patrick Gompertz), Torbay Hospital, Torbay 
(2; Debs Kelly, Isam Salih), University Hospital North Staﬀ ordshire, 
Stoke-on-Trent (9; Brendan Davies), University Hospital Wales, Cardiﬀ  
(1; Hamsaraj Shetty), University Hospitals of Leicester (2; Amit Mistri), 
William Harvey Hospital, Ashford (2; David Hargroves), Yeovil District 
Hospital (2; Khalid Rashed) Frimley Park Hospital, Frimley 
(2; Brian Clarke), Watford General Hospital, Watford, (18; David Collas).
Australia: Austin Hospital, Melbourne (2; Richard Gerraty), Gosford 
Hospital, Gosford (3; Jon Sturm), John Hunter Hospital, New Lambton 
Panel: Research in context
Systematic review
We searched PubMed on Jan 23, 2015 with the term “(carotid 
artery OR vertebral artery OR cervical artery OR anterior 
circulation OR posterior circulation OR extracranial carotid 
artery) AND (dissection) AND (antiplatelet OR 
anticoagulant)”. We found no previous randomised 
controlled trials examining whether antiplatelet or 
anticoagulant drugs are the better treatment.
Interpretation
This study was the ﬁ rst randomised controlled trial of 
dissection. We recruited 250 patients with extracranial 
carotid and vertebral artery dissection within 7 days of onset 
of symptoms and randomly assigned them to antiplatelet 
treatment or anticoagulant treatment for 3 months. We 
detected no diﬀ erence between treatment groups for 
ipsilateral stroke or death. Only 2% of participants had 
recurrent stroke at 3 months, which is lower than that 
reported in previous studies. 20% of dissections were not 
conﬁ rmed after central review of imaging, suggesting criteria 
for diagnosis are not correctly applied in all cases.
Articles
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(4: Chris Levi), Royal Adelaide Hospital, Adelaide, (6; Tim Kleinig), 
Royal Brisbane and Women’s Hospital, Brisbane (1; Andrew Wong), 
Royal Melbourne Hospital, Melbourne (1; Peter Hand), Royal Prince 
Alfred Hospital (1; Candice Delcourt).
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